-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LypfkSEAh2SimE7eb4jM+EoDX7uyCerYpGXP7XsI6Cn470eDW66Rispufw1xSF/6 cxUjtztqIZm/pTo2H/zQwA== 0000950137-04-009006.txt : 20041026 0000950137-04-009006.hdr.sgml : 20041026 20041026164118 ACCESSION NUMBER: 0000950137-04-009006 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20041026 DATE AS OF CHANGE: 20041026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSANTE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001023024 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 582301143 STATE OF INCORPORATION: WY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-116110 FILM NUMBER: 041097094 BUSINESS ADDRESS: STREET 1: 111 BARCLAY BLVD STE 280 CITY: LINCOLNSHIRE STATE: IL ZIP: 60069 MAIL ADDRESS: STREET 1: 111 BARCLAY BLVD STE 280 CITY: LINCOLNSHIRE STATE: IL ZIP: 60069 FORMER COMPANY: FORMER CONFORMED NAME: BEN ABRAHAM TECHNOLOGIES INC DATE OF NAME CHANGE: 19991027 424B3 1 c89062b3e424b3.htm PROSPECTUS SUPPLEMENT e424b3
 

     
PROSPECTUS SUPPLEMENT NO. 1
(to Prospectus Dated June 25, 2004)
  Filed Pursuant to Rule 424(b)(3)
File No. 333-116110


(BIOSANTE LOGO)

3,483,996 Shares

Common Stock


This Prospectus Supplement No. 1 supplements the prospectus dated June 25, 2004 relating to the 3,483,996 shares of common stock of BioSante Pharmaceuticals, Inc. that may be offered for sale for the account of several stockholders of BioSante, their respective donees or pledgees, as stated under the heading “Plan of Distribution” in the original prospectus.

This Prospectus Supplement No. 1 is being filed to update the original table of Selling Stockholders in the original prospectus with respect to a change in beneficial ownership that has occurred since the date of the original prospectus. This Prospectus Supplement No. 1 is not complete without, and may not be delivered or utilized except in connection with, the original prospectus. This Prospectus Supplement No. 1 is qualified by reference to the original prospectus, except to the extent that the information contained in this Prospectus Supplement No. 1 supersedes the information contained in the original prospectus.

SELLING STOCKHOLDERS

The table of selling stockholders in the original prospectus lists The Richard H. Aldrich Living Trust dated January 25, 2001 as the beneficial owner of 457,200 shares of BioSante common stock, 115,000 shares, including 15,000 shares issuable upon exercise of a warrant of which could be offered for sale by this stockholder pursuant to the original prospectus. On September 28, 2004, The Richard H. Aldrich Living Trust made a contribution of 100,000 shares of BioSante common stock and a warrant to purchase 15,000 shares of BioSante common stock to RA Capital Biotech Fund, LP. The table of selling stockholders as it relates to the shares of BioSante common stock listed as held by The Richard H. Aldrich Living Trust dated January 25, 2001 in the original prospectus is hereby updated through October 26, 2004 and amended to reflect the foregoing as follows:

                                                 
                                    Shares Beneficially
                                    Owned After
    Shares Beneficially           Completion of
    Owned Prior to the Offering
    Number of     the Offering
    Shares Subject to   Total Shares           Shares        
    Options, Warrants, and   Beneficially           Being        
Selling Stockholder
  Class C Special Stock
  Owned
  Percentage
  Offered
  Number
  Percentage
RA Capital Biotech Fund, LP(1)
    15,000       115,000       *       115,000       0        


*   Less than one percent (1%)

(1)   RA Capital Management, LLC is the general partner of RA Capital Biotech Fund, LP. Richard H. Aldrich is the sole managing member of RA Capital Management, LLC and as such has sole voting and dispositive power over the BioSante securities held by RA Capital Biotech Fund, LP.

 


 

The common stock offered involves a high degree of risk. We refer you to “Risk Factors,” beginning on page 8 of the original prospectus.


Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this Prospectus Supplement No. 1 is truthful or complete. Any representation to the contrary is a criminal offense.


The date of this Prospectus Supplement No. 1 is October 26, 2004

 

GRAPHIC 2 c89062b3c8906201eo2.gif GRAPHIC begin 644 c89062b3c8906201eo2.gif M1TE&.#=ATP!>`/<``````(````"``("`````@(``@`"`@,#`P,#/($.*'$FRI,F3*%.J7,FRI"((*#8JS:-&=-XTJ7 M3K-JW9H5*4^N8)//*)7O7K5^_ M?/4*'DRX\-RZAA/W/9#`GD%[[NM>O7L%]ODT9;VV78XTIWIBUM6^S?P'4+!QU[>.>SCR-;9DV.,=*Y M7G>6E8R9W%F[RHUGMAX=+5_I<.KMY[F&MTI5L>W+S MHN[+6V<<'R?<=NJI1TYC5J47X#;L$029@:VU@YI$-0%H&VWD(#"0/0<8J-U; M#T)(UX'D#4A0`AJJE^"%^?EF78<184@=A0_65*)P`[+8XH<@&B?B0"3F.-F) M`BUH68,=9G60C+-)4R-.*0ZWXI%@,0:@CS0F,.*,Y`'YCY"5$7EA67\1F%H" MLVTS#ENMFBCEER^Y^"%6*JXYXBD]>:G>)+Q=IF5 M"D;69WG:&*I;H]+4=QNB=2Z:)&VCX9FBET&2@^EEF)+#(IFBA6H64I$Y6AFE MG28IYS:0"O^JFZI#LFKG9KS)"IJF##[9Z:>629.,DJS^0ZI]L&EFW77R-3E9 ML21*$XVNHS7HIFS;N:EH:[EU20X[9A4I'CMPSLCK; MJ$DN&6&O9^&4FD]F608M.8W"*QI\7.%8V9D$:D76>/G2]%BS]-G'&%9-W4K9 MNM[^N>6EN?(&WX@`PGBAQ4(66VG6EC M0BA+X^#.8Q[`CGWYGJPAQGK&^&YF9UDXUE1RY.26<\U;%O48F3XG]3!--BG'#8=7*V7QC\5NN6F["P+_Q\Y7(RLG MUUW-RDX7YDZ:XZ4PU>R-:L5=82UBLUU'1NN3G1JD]9=9&K8^[5T-7A5C9SB@>) M89GM&JLHN-==6:OTF)$>Y'S`=6L9TK$#S5#KLVDCZI?4\>WL^#QFE[M$V&/V MM:%%\\A\S<>N%V-^N=]MGZU0OT\MWF2SG/<6`K[!;6EJ)[+'.(`UF=ZH[D.] M:=H`%4(6W^W*>L::7X?8-AE(T0E)YN%?=398*-%PST_`&QOM*&-`%_UH@ZZJ MC`.+I#6:B>E&!]`>T=[B%;G0JS?-JQ_S_V[7)1%>1G:G0TR33LBI.@G/;81[ M4=3(]T)`,;!,CKO>D"X7'=/M!''I(9A3"J(U(-(O6/.B8@BIU\$((@YS<#O: MZ_:F,7OTB8IPVG.4[][&]86 MQ[DSRC"-42PB&UWE1Z,=<8[X4AK8+A.P1M;)=FH\HRG]N+S1R"N!T=J&]8+G M'-/]\),PO&4C7;A&'AG(-FAC$\5RXI-*MB>8?/I?`X>U/L9M$X&VBB%EHB'- MQ?F.E?YKA].N)_^9#V)/-A^3GQFSR4)<.E*7WL0,_;8%''4!4X#IS(RTB$7+ M/5+G;PKR%+4DD^ M<:9Y_P@E2XEVO^UL4&ASPJ`+/R@XD"H)I;4D:`,-RLW]@6R0OA'A1-\W4TLF M[4MNNN&7D)G+1N4.0U-K#6,2U:7K&$8JB,N-/YT5OV/VIG/RTR81NWF])DUS M86::'.4<:M7N*6B,`;3H4L.)E)YH+H8-X\J1(#@.U07O<]>$ZS'EJD;*O"XM MJ(-+C'R".7,F"IT4`:%@0SA)%"&VM#S;W`PIDE*E#K&RD^EEX,J'-I[_>19% MH/60G4;+NTG&,7Q5K$C?RM361&H04)3-I>LP.!#&T):Y"+'C+_N*PO[P:SR1 MLA?L_"2V-?'+@C_J;GPJ.,A#CK-@\TM831B9L-V55;U6P5]2G**_$YH)7=I" MTV;0A*53M==@U([PC^7,EO\,^;YL(8L[%MWG\$!YNX@.,Y?#F&9`X_DOAKZQI"_, ML$T#FLR:AO&.D]C@\BT+P1EN\V>_/..&HEG)5C8SS=)E:A^'T3KEO+9^^\)(/?;$*SGE[M"[;:\Y553J9_M/A3-F8,F!6LK+<`F\:H]EJ4WHR)C[+.BV\'_H`E7/V#?>:FEXML4Z2O/A?7][ MT&\&-LT&7NZ#76?2`?]FM[..\^[)0-SB\Q9YM97LXVAO?$X>SXY??N.7]ZJ% MX+.6=;TK.)V47UI;[(#JPV?L&5O7F^;3MKF_!Y9SVG(YR.,6])5-3G0+DSJK M2VQYI$%-Y)O/'-0S!OK$":P9Z)F%W[&[=&#"0^^1_[SD]?Y/TN[\&-_E94/Y@*3$9P^E2NM@]7^[R`]-^BPM?.6>6OFEU__[QX;:OM.9VAWE4 MT,6/H'8@>._0+XM[0T-]2>NXU=JS-;Y@S?IKE:;(E#Y=TKV5_"6J!?TU=FF7 MYW"[5W\3MAR_5V"#)FU0MVDZ]AZZ-GQCQF2OD6CND67\Q1P%)V3!_Z%JN,5J M_.5J$GAVV/9)W!!%:8AV!=MKS8> ML=8^X^=?HT-JZ0%A3L(=A)&``K=O=T&$`G>"_F5H-C@Z@Q%V@+>#-V5V\/=L MK*=C(U@:8'9T]@=[VE(Y(*9E&WB`?^=L!P-MFM$;<]-ZR5)V$*8NI4'.!AE(+AXIF=!M@9>DB(A9AL MKK$9>U4)RW:* MNG$JSP*#(*<=#2*&+VB+HH$P=/^AB@%B7V@V=WCQBB/G:`&R'VVA M&-/A?<38?%UGC>X&>&A6&".X'WPA???G%M18C=<8&NN6<-IH0F*W:R5V?`5G MB7BX:29VCI]Q;KFXB@689Y8H8>L(&LPAB$\FC_8(>_]X08!W7[38B,7C&J08 M(@O)B079=`RIBV(WD1B9D1K)<@FYD1[YD1EI7\CB:O*RAR!YDC@C,"X7B\#( MDNR8D*D#'JA2;.2&DC9I)F$CCH2$C)\ADO82'34!)G`3?#>9D><1?*YWD/$2 M50#&?A2.&A(RQ=\MB+5I)*$B&7W;&0W!7>/*&+EF)(PT" M=-_B9`12%M!3/@;_(W]+!6+A"#!,*2%65DWD!T!LV"6.(2.P(396,Y2-(6*N MPBSQI5:SMR1`98+^54&2\18]`6#&"#&\XQ7*,0V^84U4V6]E@6RC@QI@]1]$ M\UR-H1/M$T'SA3)W*3'J99B=>#Y_64,THS:K\Y<8XCO-<5[W,B!V,9@92NL(9BD`U9?`9CP\1T$$C>"Z1QQ]#=!R1]',5^I)$F$.9Z:]5C\LIGZ MF11?)$3M95BZXQS:&9S_A9D-4IA>D9N-48WM.9QPHWLP*9I`Z1,F8T@__Z.= M[:4X$4(@VGD=\!%6B")=405"#?-%X_E;L]9/%HI(14&;L240""!6+&I#AT03 MK;.5W4F5_&$7N?DM5K(43^1(MV34=^0(@ MT9`,VH`H9)((R7!*=L(A4[FB?[1),B89[%"?SIE3EG$`-/HL.BHLAL(=.0H9 MPC(LJZ=6<`2DV).3[E91C$?>V*G3EHCP>F;X3B8=%&8&B4Z"\JDPK*E MQ^2E8$H=8JE^C.H8;&.F/)JF5`F=%&,L/H@H-=26#$2G2](.=QI!7@D>UL2G MBM*>T(&,XKDE"-!S2F(ARR,HB"J$N=9>4[IEC?\A(1R504YZ&G;RH,%9-#7Q ME^W0+36R,--*(L$(60;G*Z1B-21B5@M:IW9R'HTZE-;"H,H*($?Y?S=:;!6J M.Q+UI4-*FR-Z9ZM#GW4RK`_6$U-B&UQ:+XX:56DSG;K#J&AU0'#JH^UY*L'S M(-M*ID@R(`H[L)DC(R7J'?)1F+,J'Z!CHJX#D]4I*[8!*=M@H/"6.ONFIMAA M%U)F$]3!KW81/N=&':^)F8@I'Y\YLLX9-Y.36*CYLE7S7R$:C/1I%5:ZFK_I M'=7XG3G!LK$9;MQR4RZY>BX7>J,8M=[RA[=&>J46BST8>7(Y?HWHAO8AK;86 M?R$XBF3I:['YD.I!.>=?6)&PZ+1[J`WU89)<:"E[Q6I62V1VNX9'6I2`&[CE M@2?_%)&&>[B(F[@-HFOEH+B@Y[BP$8B0&QOD\BT9"R76E;F:N[F^[F: 6*Q.B.[JD6[JF>[JHF[JJN[H?$1``.S\_ ` end
-----END PRIVACY-ENHANCED MESSAGE-----